Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma

INTRODUCTION/AIM: Eptacog beta is a recombinant activated human factor VII approved to treat and control bleeding in haemophilia A and B patients with inhibitors. Emicizumab is a factor VIIIa mimetic antibody approved for prophylactic treatment of haemophilia A with and without inhibitors (HAI and H...

Descripción completa

Detalles Bibliográficos
Autores principales: Grandoni, Jerry, Duretz, Véronique, Bonzo, Daniel, Evans, Sean, Plantier, Jean‐Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048629/
https://www.ncbi.nlm.nih.gov/pubmed/33550714
http://dx.doi.org/10.1111/hae.14253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048629/
https://www.ncbi.nlm.nih.gov/pubmed/33550714
http://dx.doi.org/10.1111/hae.14253

Ejemplares similares